Pharmaniaga Bhd (XKLS:7081) Research & Development: RM0 Mil (TTM As of Mar. 2026)


XKLS:7081 Pharmaniaga Bhd XKLS:7081
46 GF Score
Price RM1.22
GF Value RM0.74
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pharmaniaga Bhd Research & Development?

Pharmaniaga Bhd XKLS:7081 -4.69% 46 Research & Development is RM0 Mil as of Mar. 2026. GuruFocus rates XKLS:7081 with a GF Score™ of 46/100 and a GF Value™ of RM0.74 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pharmaniaga Bhd's Research & Development for the three months ended in Mar. 2026 was RM0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was RM0 Mil.

Pharmaniaga Bhd  (XKLS:7081) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pharmaniaga Bhd Research & Development Related Terms

Pharmaniaga Bhd Research & Development Historical Data

* Premium members only.

The historical data trend for Pharmaniaga Bhd's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaniaga Bhd Research & Development Chart

Pharmaniaga Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmaniaga Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XKLS:7081
46GF Score
Pharmaniaga Bhd XKLS:7081
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaniaga Bhd Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of RM0 Mil mean?
Pharmaniaga Bhd (XKLS:7081) has a Research & Development of RM0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pharmaniaga Bhd and its competitors.
Is Pharmaniaga Bhd's Research & Development too high?
Pharmaniaga Bhd's current Research & Development is RM0 Mil. Overall, Pharmaniaga Bhd has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's Research & Development compare to MCK and CAH?
Pharmaniaga Bhd's Research & Development of RM0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pharmaniaga Bhd and its competitors. Pharmaniaga Bhd's current Research & Development is RM0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.74, compared to a current price of RM1.22 — trading 64.9% above its estimated fair value. The current Research & Development is RM0 Mil. Pharmaniaga Bhd's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current Research & Development is RM0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued. The current stock price of RM1.22 is trading 64.9% above its estimated GF Value™ of RM0.74. GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.

Key valuation signals for XKLS:7081:

  • Research & Development: RM0 Mil
  • GF Value™: RM0.74 vs. price of RM1.22 (64.9% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaniaga Bhd Business Description

Address No. 7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja, Seksyen 7, Selatan, Shah Alam, SGR, MYS, 40000
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
46GF Score

Get the complete analysis for XKLS:7081

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.22
Price
RM0.74
GF Value